185P - Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anti-Cancer Agents & Biologic Therapy
Rectal Cancer
Translational Research
Surgery and/or Radiotherapy of Cancer
Presenter Yoon Ho Ko
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors Y.H. Ko1, D.S. Sun2, H.S. Won2, M.A. Lee3, S.U. Hong4, J. Jung5, H. Cho6, B. Shim7
  • 1Medical Oncology, Uijeongbu St. Mary's Hospital, 480-717 - Uijeongbu City/KR
  • 2Medical Oncology, Uijeongbu St. Mary's Hospital, Uijeongbu City/KR
  • 3Medical Oncology, Seoul St. Mary's Hospital, of the Catholic University, Seoul/KR
  • 4Pathology, Chung-Ang University Hospital, Seoul/KR
  • 5Pathology, St Vincent Hospital The Catholic University of Korea, Suwon/KR
  • 6Surgery, St Vincent Hospital The Catholic University of Korea, Suwon/KR
  • 7Medical Oncology, St Vincent Hospital The Catholic University of Korea, 442-723 - Suwon/KR

Abstract

Aim/Background

Autophagy, a cellular degradation process, has complex roles in tumourigenesis and resistance to cancer treatment in humans. The aim of this study was to explore the expression levels of autophagy-related proteins in patients with rectal cancer and evaluate their clinical role in the neoadjuvant chemoradiotherapy setting.

Methods

All specimens evaluated were obtained from 101 patients with colorectal cancer who had undergone neoadjuvant chemoradiotherapy and curative surgery. The primary outcomes measured were the expression levels of two autophagy-related proteins (microtubule-associated protein 1 light chain 3 beta (LC3b) and beclin-1) by immunohistochemistry and their association with clinicopathological parameters and patient survival.

Results

Among the 101 patients, the frequency of high expression of beclin-1 was 31.7% (32/101) and that of LC3b was 46.5% (47/101). A pathologic complete response was inversely associated with LC3b expression (P = 0.003) and alterations in the expression of autophagy-related proteins (P = 0.046). In the multivariate analysis, however, autophagy-related protein expression did not show prognostic significance for relapse-free survival or overall survival.

Conclusions

High expression of autophagy-related proteins shows a strong negative association with the efficacy of neoadjuvant chemoradiotherapy in patients with rectal cancer. Autophagy has clear implications as a therapeutic target with which to improve the efficacy of neoadjuvant chemoradiotherapy.

Clinical trial identification

nothing to declare

Disclosure

All authors have declared no conflicts of interest.